GT Biopharma, Inc. (NASDAQ: GTBP)

GT Biopharma, Inc. (GTBP), a clinical-stage biopharmaceutical company, operates in the immuno-oncology industry. Its primary business activities revolve around the development of novel immuno-oncology products based on its unique Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. This platform generates proprietary therapeutics designed to enhance the cancer-killing abilities of a patient's natural killer (NK) cells.

The company's revenue generation is centered on the development and commercialization of its TriKE platform, which includes three primary products: GTB-3550, GTB-3650, and GTB-5550. These products are designed to target various types of cancer, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and solid tumors. GTB-3550 is a TriKE construct that targets CD33 on the surface of myeloid leukemias, while GTB-3650 is a next-generation camelid nanobody TriKE that also targets CD33 on myeloid leukemias. GTB-5550, on the other hand, targets B7-H3 on the surface of advanced solid tumors.

The TriKE platform has several advantages, including its ability to target a variety of tumor antigens, its scalability, and its potential to be used as both monotherapy and in combination with other standard-of-care therapies. The company believes that its TriKE platform has the potential to overcome some of the limitations of chimeric antigen receptor (CAR) T-cell therapy and other antibody therapies.

For instance, the company's GTB-3550 TriKE construct has been studied in a Phase 1 clinical trial in patients with CD33-positive leukemias, including AML and MDS. The trial showed that the therapy was overall well-tolerated and safe, with no serious cases of cytokine release syndrome observed. Four of twelve patients had transient reductions in bone marrow leukemic blast cells, and correlative studies showed activation, proliferation, and persistence of functionally active endogenous NK cells.

Similarly, preclinical studies of GTB-3650 have shown that this molecule has NK-cell targeted activity against a variety of solid tumor settings, including head and neck cancer, prostate cancer, breast cancer, ovarian cancer, glioblastoma, and lung cancer. GTB-5550, which targets B7-H3, has shown NK-cell targeted activity against a variety of solid tumor settings, including bladder, breast, cervical, colorectal, endometrial, esophageal, gastric, glioma, kidney, liver, lung, pancreatic, prostate, head and neck cancer, and melanoma.

In terms of competition, GT Biopharma competes with other biopharmaceutical companies that are developing immuno-oncology products, including CAR-T cell therapies and antibody therapies. However, the company believes that its TriKE platform has the potential to differentiate itself from these competitors and provide a unique therapeutic approach for the treatment of various types of cancer.

Currently, GT Biopharma does not have any customers as it is still in the development stage. However, it expects to have customers in the future, including hospitals, research institutions, and pharmaceutical companies.